Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594593 | SCV000708480 | uncertain significance | not provided | 2017-05-08 | criteria provided, single submitter | clinical testing | |
3billion | RCV001358772 | SCV003841624 | likely pathogenic | Hypercholanemia, familial, 2 | 2023-02-23 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.024%). Protein truncation variants are a common disease-causing mechanism. Functional studies provide moderate evidence of the variant having a damaging effect on the gene or gene product (PMID: 24867799). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.87; 3Cnet: 0.11). Same nucleotide change resulting in same amino acid change has been previously reported to be associated with SLC10A1-related disorder (ClinVar ID: VCV000501945 / PMID: 24867799). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. |
Molecular Genetics and NGS Laboratory, |
RCV001358772 | SCV004101390 | pathogenic | Hypercholanemia, familial, 2 | 2023-11-07 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000594593 | SCV005191456 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
OMIM | RCV001358772 | SCV001554648 | pathogenic | Hypercholanemia, familial, 2 | 2021-04-07 | no assertion criteria provided | literature only | |
Prevention |
RCV003392438 | SCV004110871 | likely pathogenic | SLC10A1-related disorder | 2024-02-16 | no assertion criteria provided | clinical testing | The SLC10A1 c.755G>A variant is predicted to result in the amino acid substitution p.Arg252His. This variant in the homozygous state has been reported in a patient with extremely elevated plasma bile salt levels, without clinical signs of pruritus, cholestasis, or liver dysfunction (Vaz et al. 2015. PubMed ID: 24867799; Vaz et al. 2017. PubMed ID: 28249272; Erlinger. 2015. PubMed ID: 25193235). Functional analysis showed that this variant resulted in a significantly reduced uptake activity of taurocholic acid (Vaz et al. 2015. PubMed ID: 24867799). This variant is reported in 0.042% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/). This variant is interpreted as likely pathogenic. |